The lung in amyloidosis

P Milani, M Basset, F Russo, A Foli… - European …, 2017 - Eur Respiratory Soc
Amyloidosis is a disorder caused by misfolding of autologous protein and its extracellular
deposition as fibrils, resulting in vital organ dysfunction and eventually death. Pulmonary …

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy …

…, S Perlini, R Albertini, P Russo, A Foli… - Blood, The Journal …, 2010 - ashpublications.org
In light-chain (AL) amyloidosis, prognosis is dictated by cardiac dysfunction. N-terminal
natriuretic peptide type B (NT-proBNP) and cardiac troponins (cTn) are used to assess the …

Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis

…, MA Dimopoulos, JP Fermand, A Foli… - Journal of Clinical …, 2020 - discovery.ucl.ac.uk
PURPOSE: Oral melphalan and dexamethasone (MDex) were considered a standard of care
in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used …

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

…, MA Dimopoulos, T Lane, A Foli… - Blood, The Journal …, 2013 - ashpublications.org
Abstract Treatment outcomes of patients with cardiac stage III light chain (AL) amyloidosis
remain poorly studied. Such cases have been excluded from most clinical studies due to …

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

…, P Milani, C Kimmich, A Foli… - Blood, The Journal …, 2014 - ashpublications.org
The kidney is involved in 70% of patients with immunoglobulin light-chain (AL) amyloidosis,
but little is known on progression or reversibility of renal involvement, and criteria for renal …

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

…, P Milani, J Gillmore, A Foli… - Blood, The Journal …, 2015 - ashpublications.org
The combination of cyclophosphamide/bortezomib/dexamethasone (CyBorD) showed early
promise of high rates of hematologic responses tempered by studies showing the inability to …

Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns

J Lisziewicz, A Foli, M Wainberg, F Lori - Drug safety, 2003 - Springer
Data from basic science and clinical studies suggest that hydroxyurea (hydroxycarbamide)-based
regimens are effective treatment options for patients with HIV at various stages of …

Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure

G Palladini, A Foli, P Milani, P Russo… - American journal of …, 2012 - Wiley Online Library
In AL amyloidosis prognosis depends on the severity of heart dysfunction which is best
assessed by natriuretic peptides (BNP and NT‐proBNP). However, their clearance relies on …

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome

P Milani, M Basset, F Russo, A Foli… - Blood, The Journal …, 2017 - ashpublications.org
The validated criteria of hematologic response in light-chain (AL) amyloidosis are based on
the measurement of circulating free light chains (FLCs). Patients with a difference between …

A practical approach to the diagnosis of systemic amyloidoses

…, P Morbini, C Klersy, F Lavatelli, A Foli… - Blood, The Journal …, 2015 - ashpublications.org
Accurate diagnosis of systemic amyloidosis is necessary both for assessing the prognosis
and for delineating the appropriate treatment. It is based on histologic evidence of amyloid …